Bates DO - Search Results

1

VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo.

Rennel ES, Varey AH, Churchill AJ, Wheatley ER, Stewart L, Mather S, Bates DO, Harper SJ. Rennel ES, et al. Among authors: bates do. Br J Cancer. 2009 Oct 6;101(7):1183-93. doi: 10.1038/sj.bjc.6605249. Epub 2009 Aug 25. Br J Cancer. 2009. PMID: 19707198 Free PMC article.

2

VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.

Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. Bates DO, et al. Cancer Res. 2002 Jul 15;62(14):4123-31. Cancer Res. 2002. PMID: 12124351

3

Therapeutic potential of inhibitory VEGF splice variants.

Bates DO, Harper SJ. Bates DO, et al. Future Oncol. 2005 Aug;1(4):467-73. doi: 10.2217/14796694.1.4.467. Future Oncol. 2005. PMID: 16556023 Review.

4

VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice.

Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA. Konopatskaya O, et al. Among authors: bates do. Mol Vis. 2006 May 26;12:626-32. Mol Vis. 2006. PMID: 16735996 Free article.

5

Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm.

Ladomery MR, Harper SJ, Bates DO. Ladomery MR, et al. Among authors: bates do. Cancer Lett. 2007 May 8;249(2):133-42. doi: 10.1016/j.canlet.2006.08.015. Epub 2006 Oct 5. Cancer Lett. 2007. PMID: 17027147 Review.

6

Recombinant human VEGF165b protein is an effective anti-cancer agent in mice.

Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, Magnussen A, Schüler Y, Kelly SP, Finucane C, Ellison D, Cebe-Suarez S, Ballmer-Hofer K, Mather S, Stewart L, Bates DO, Harper SJ. Rennel ES, et al. Among authors: bates do. Eur J Cancer. 2008 Sep;44(13):1883-94. doi: 10.1016/j.ejca.2008.05.027. Epub 2008 Jul 24. Eur J Cancer. 2008. PMID: 18657413 Free PMC article.

7

Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.

Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO. Nowak DG, et al. Among authors: bates do. J Cell Sci. 2008 Oct 15;121(Pt 20):3487-95. doi: 10.1242/jcs.016410. J Cell Sci. 2008. PMID: 18843117 Free PMC article.

8

VEGF-A splicing: the key to anti-angiogenic therapeutics?

Harper SJ, Bates DO. Harper SJ, et al. Among authors: bates do. Nat Rev Cancer. 2008 Nov;8(11):880-7. doi: 10.1038/nrc2505. Epub 2008 Oct 16. Nat Rev Cancer. 2008. PMID: 18923433 Free PMC article. Review.

9

Therapeutic potential of manipulating VEGF splice isoforms in oncology.

Rennel ES, Harper SJ, Bates DO. Rennel ES, et al. Among authors: bates do. Future Oncol. 2009 Jun;5(5):703-12. doi: 10.2217/fon.09.33. Future Oncol. 2009. PMID: 19519209 Free PMC article. Review.

10

Molecular diversity of VEGF-A as a regulator of its biological activity.

Woolard J, Bevan HS, Harper SJ, Bates DO. Woolard J, et al. Among authors: bates do. Microcirculation. 2009 Oct;16(7):572-92. doi: 10.1080/10739680902997333. Epub 2009 Jun 1. Microcirculation. 2009. PMID: 19521900 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

203 results

Search Page

Filters